Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
mRNAs containing a constitutive decay element (CDE) are a specific class of transcripts characterized by a conserved stem-loop motif in their 3' untranslated region (UTR) (Stoecklin et al., 2006). This element serves as a recognition site for RNA-binding proteins, primarily Roquin-1 (RC3H1) and Roquin-2 (RC3H2), which trigger rapid mRNA degradation (Leppek et al., 2013). The CDE-mediated decay pathway is distinct from the more common AU-rich element (ARE) pathway and is essential for the post-transcriptional regulation of pro-inflammatory mediators, such as Tumor Necrosis Factor (TNF) (Janowski et al., 2016). In a healthy state, this mechanism prevents the overproduction of cytokines; however, dysregulation of the CDE-Roquin interaction is linked to autoimmune diseases and chronic inflammation (Vogel et al., 2013). Therapeutic interest lies in modulating this interaction to either stabilize beneficial mRNAs or accelerate the decay of pathogenic ones (Heissmeyer & Vogel, 2013). While direct small-molecule targeting of the CDE motif is in early research stages, it represents a precise approach to controlling gene expression at the RNA level. The recruitment of the CCR4-NOT deadenylase complex by Roquin is the primary effector mechanism for these targets (Bulani et al., 2015). Mutations in the proteins that recognize these elements, such as the sanroque mutation in Roquin, lead to severe autoimmune phenotypes (Vinuesa et al., 2005).
Recruitment of Roquin proteins (RC3H1 and RC3H2) to the CDE stem-loop motif, which subsequently recruits the CCR4-NOT deadenylase complex to initiate rapid mRNA decay (Leppek et al., 2013; Bulani et al., 2015).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on mRNAs containing a constitutive decay element (CDE) (CDE-mRNA).